EKF Diagnostics (LON:EKF) Stock Crosses Below 200-Day Moving Average of $58.76

EKF Diagnostics Holdings plc (LON:EKFGet Rating)’s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 58.76 ($0.72) and traded as low as GBX 34.50 ($0.43). EKF Diagnostics shares last traded at GBX 34.60 ($0.43), with a volume of 220,897 shares.

The company has a 50-day simple moving average of GBX 39.87 and a 200-day simple moving average of GBX 58.59. The stock has a market cap of £157.41 million and a PE ratio of 10.18. The company has a debt-to-equity ratio of 2.78, a current ratio of 3.48 and a quick ratio of 2.35.

The firm also recently disclosed a dividend, which will be paid on Thursday, December 1st. Shareholders of record on Thursday, November 3rd will be given a GBX 1.20 ($0.01) dividend. This is a boost from EKF Diagnostics’s previous dividend of $1.10. The ex-dividend date of this dividend is Thursday, November 3rd. This represents a yield of 2.35%. EKF Diagnostics’s dividend payout ratio is presently 29.41%.

In other news, insider Christopher H. B. Mills purchased 1,275,000 shares of the company’s stock in a transaction dated Thursday, April 28th. The stock was acquired at an average price of GBX 35 ($0.43) per share, for a total transaction of £446,250 ($550,110.95).

EKF Diagnostics Company Profile (LON:EKF)

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; DiaSpect Hemoglobin T analyzer; Hemo Control, a hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples.

Read More

Receive News & Ratings for EKF Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EKF Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.